Key Highlights

Paradigm Biopharmaceuticals Limited (ASX:PAR) lodged an announcement titled "PAR Completes Enrolment in Pivotal Phase 3" on 15 June 2026, closing recruitment into study PARA_OA_012.

The registered trial is a Phase 3, randomised, double-blind, placebo-controlled study with a target enrolment of 466 participants and a primary pain endpoint measured at Day 112.

The company's Phase 3 programme has been rebuilt and re-timed repeatedly since 2021, and the registry still lists primary completion as July 2027.

Share-price attention may centre on whether Paradigm Biopharmaceuticals delivers the operational and strategic milestones described in the update.

Paradigm Biopharmaceuticals told the ASX on 15 June 2026 that it had finished recruiting patients into the pivotal Phase 3 trial of its injectable osteoarthritis drug. It is the most consequential operational milestone the Melbourne company has reached in years, and it starts the clock running towards a data readout.

The latest financial or clinical position

Recruitment closes on the study that will decide the company Paradigm Biopharmaceuticals Limited (ASX:PAR) has stopped taking new patients into the trial that matters most to it. In an announcement lodged with the Australian Securities Exchange on 15 June 2026, headed "PAR Completes Enrolment in Pivotal Phase 3", the Melbourne-based drug developer confirmed it had finished enrolling participants into the registrational study of injectable pentosan polysulfate sodium, which the company abbreviates to iPPS, for pain caused by knee osteoarthritis.

For a company with no approved product and a market value of roughly AUD 99 million, that is a genuine turning point. Recruiting patients is the slowest and least controllable part of drug development. Once the last participant is in, the remaining timeline is largely arithmetic.

Products, programmes and commercial context

What Phase 3 actually means, and what this one measures Drug development runs in stages. Phase 1 checks safety in small numbers of people. Phase 2 looks for early signs that a drug works and helps choose a dose. Phase 3 is the large, confirmatory stage regulators such as the United States Food and Drug Administration rely on when deciding whether to approve a medicine. It is called pivotal because the approval decision pivots on it.

The next evidence and execution test

Enrolment is the process of screening, consenting and randomly assigning eligible patients into the study. Completing it means no further patients will be recruited, so the sample size is now fixed.

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals told the ASX on 15 June 2026 that it had finished recruiting patients into the pivotal Phase 3 trial of its injectable osteoarthritis drug. It is the most consequential operational milestone the Melbourne company has reached in years, and it starts the clock running towards a data readout. The company’s position remains linked to the operational, financial and strategic developments detailed in the supplied article.

What Investors May Watch Next

Delivery against reported guidance and milestones

Product adoption or clinical programme progress

Cash use, funding and commercial investment

Regulatory developments and the PAR share-price response

Risks

The company faces clinical, regulatory, commercialisation, reimbursement, competition, funding and execution risks. Guidance and development timelines are forward-looking and may change. The supplied information is a point-in-time summary and does not establish future operational or share-price performance.